Why the study?
Systemic side effects of existing PAH vasodilator therapies and challenges with inhaled options often limit optimal dosing, particularly in combination regimens.
Is long-term frespaciguat safe and tolerable in patients with pulmonary arterial hypertension?
Is long-term frespaciguat safe and tolerable in patients with pulmonary arterial hypertension?
Supports exploration of less frequent inhaled PAH regimens to curb side effects; leaves open efficacy and safety in prospective trials.
Extract Pulmonary arterial hypertension (PAH) is a progressive, life-threatening disease requiring long-term management to prevent right ventricular failure and improve outcomes [1, 2]. Despite advancements in PAH vasodilator therapies targeting the endothelin, prostacyclin, and nitric oxide pathways, systemic side effects remain a challenge that often limit optimal dosing, particularly with use of combination regimens [3]. While inhaled options exist, frequent administration and systemic side effects pose challenges [4, 5].
No takes yet. Share an insight, caveat, or question.
Humbert et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: